ECM
PBYI icon

Element Capital Management’s Puma Biotechnology PBYI Stock Holding History

Element Capital Management’s Portfolio PBYI Stock Details PBYI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-10,228
Closed -$397K – 594
2019
Q1 		$397K Buy
+10,228
New +$312K 0.01% 510

Other funds holding PBYI

State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.17B AUM 92.19% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SCM
Sarissa Capital Management Greenwich, Connecticut $178M AUM 118.43% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return
FAM
Fred Alger Management New York $30B AUM 76.99% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $23.2B AUM 40.19% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return

Element Capital Management's PBYI Position: Q2 2019 in Review

Element Capital Management sold out of Puma Biotechnology (PBYI) in Q2 2019, closing a stake of 10,228 shares — an estimated $397K sold.

Element Capital Management first reported a position in PBYI in Q1 2019 and held it in 1 quarter. The position peaked at $397K in Q1 2019. 139 funds tracked by Wall St. Rank hold PBYI as of Q2 2019.

  • Element Capital Management reported no remaining Puma Biotechnology position as of Q2 2019 after selling out during the quarter.
  • Element Capital Management sold 10,228 Puma Biotechnology shares in Q2 2019, an estimated $397K.
  • Element Capital Management first reported a position in Puma Biotechnology in Q1 2019 and held it in 1 quarter.
  • Element Capital Management's Puma Biotechnology position peaked at $397K in Q1 2019.
  • 139 funds tracked by Wall St. Rank held Puma Biotechnology as of Q2 2019.

Based on Element Capital Management's 13F filing for Q2 2019, filed 14 Aug 2019.